• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

芬兰的遗传性尿素循环疾病。

Hereditary urea cycle diseases in Finland.

作者信息

Keskinen Päivi, Siitonen Anna, Salo Matti

机构信息

Department of Pediatrics, Tampere University Hospital, Tampere, Finland.

出版信息

Acta Paediatr. 2008 Oct;97(10):1412-9. doi: 10.1111/j.1651-2227.2008.00923.x. Epub 2008 Jul 9.

DOI:10.1111/j.1651-2227.2008.00923.x
PMID:18616627
Abstract

AIM

To estimate the incidence of urea cycle diseases (UCDs) in Finland and determine the course of the various disorders as well as the outcome.

METHODS

The original data were collected in the years 1998-2001. The diagnoses made after 2001, as well as the current status of the patients, were updated by surveys in the spring of 2007.

RESULTS

We found a total of 55 cases of UCDs in Finland by 2007: 30 cases of ornithine transcarbamylase (OTC) deficiency, 20 of argininosuccinate lyase (ASL) deficiency, 3 of carbamyl phosphate synthetase (CPS-I) deficiency, 1 of type 1 citrullinaemia and 1 of argininaemia. The estimated total incidence of UCDs was 1:39 000. The incidences of individual disorders were: OTC deficiency 1:62 000, ASL deficiency 1:144 000, CPS deficiency 1:539 000 and citrullinaemia 1:1 616 000. Eighteen (33%) of the patients with a diagnosis of UCD have died, most during their first hyperammonaemic crisis. One patient with OTC deficiency has had a liver transplant. Neurological symptoms of varying severity are common among these patients, particularly those with ASL deficiency.

CONCLUSION

The first survey on the incidence of UCDs in Finland shows some differences in the occurrence rates compared to other countries. Hyperammonaemia, and the neurological symptoms caused by it, can be avoided in most patients with late-onset UCDs with a standard treatment. However, in patients with ASL deficiency, the development of neurological symptoms seems to be inevitable in spite of careful treatment and avoidance of hyperammonaemia.

摘要

目的

评估芬兰尿素循环障碍(UCDs)的发病率,确定各种疾病的病程及预后。

方法

原始数据收集于1998 - 2001年。2001年后做出的诊断以及患者的当前状况,通过2007年春季的调查进行更新。

结果

到2007年我们在芬兰共发现55例UCDs患者:30例鸟氨酸转氨甲酰酶(OTC)缺乏症,20例精氨琥珀酸裂解酶(ASL)缺乏症,3例氨甲酰磷酸合成酶(CPS - I)缺乏症,1例1型瓜氨酸血症和1例精氨酸血症。UCDs的估计总发病率为1:39000。各疾病的发病率分别为:OTC缺乏症1:62000,ASL缺乏症1:144000,CPS缺乏症1:539000,瓜氨酸血症1:1616000。18例(33%)诊断为UCD的患者已死亡,多数死于首次高氨血症危机。1例OTC缺乏症患者接受了肝移植。这些患者中不同程度的神经症状很常见,尤其是ASL缺乏症患者。

结论

芬兰首次关于UCDs发病率的调查显示,与其他国家相比发病率存在一些差异。大多数迟发性UCDs患者通过标准治疗可避免高氨血症及其引起的神经症状。然而,对于ASL缺乏症患者,尽管进行了精心治疗并避免了高氨血症,神经症状的发展似乎仍不可避免。

相似文献

1
Hereditary urea cycle diseases in Finland.芬兰的遗传性尿素循环疾病。
Acta Paediatr. 2008 Oct;97(10):1412-9. doi: 10.1111/j.1651-2227.2008.00923.x. Epub 2008 Jul 9.
2
Urea cycle disorders: clinical presentation outside the newborn period.尿素循环障碍:新生儿期以外的临床表现
Crit Care Clin. 2005 Oct;21(4 Suppl):S9-17. doi: 10.1016/j.ccc.2005.05.007.
3
Urea cycle disorders in Thai infants: a report of 5 cases.泰国婴儿的尿素循环障碍:5例报告
J Med Assoc Thai. 2002 Aug;85 Suppl 2:S720-31.
4
Histopathological findings in livers of patients with urea cycle disorders.尿素循环障碍患者肝脏的组织病理学发现。
Mol Genet Metab. 2013 Mar;108(3):161-5. doi: 10.1016/j.ymgme.2013.01.006. Epub 2013 Jan 23.
5
[Urea cycle disorders].[尿素循环障碍]
Ryoikibetsu Shokogun Shirizu. 1995(8):367-9.
6
[Molecular basis of urea cycle disorders].[尿素循环障碍的分子基础]
Nihon Rinsho. 1993 Feb;51(2):520-4.
7
Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes.一项为期21年的多中心急性高氨血症发作研究中260例尿素循环障碍患者的诊断、症状、发病率及死亡率
Acta Paediatr. 2008 Oct;97(10):1420-5. doi: 10.1111/j.1651-2227.2008.00952.x. Epub 2008 Jul 17.
8
Current role of liver transplantation for the treatment of urea cycle disorders: a review of the worldwide English literature and 13 cases at Kyoto University.肝移植在尿素循环障碍治疗中的当前作用:对全球英文文献及京都大学13例病例的综述
Liver Transpl. 2005 Nov;11(11):1332-42. doi: 10.1002/lt.20587.
9
Urea cycle enzymopathies.尿素循环酶病
Semin Liver Dis. 1982 Nov;2(4):329-39. doi: 10.1055/s-2008-1040719.
10
Developmental outcomes with early orthotopic liver transplantation for infants with neonatal-onset urea cycle defects and a female patient with late-onset ornithine transcarbamylase deficiency.新生儿期起病的尿素循环障碍婴儿及迟发性鸟氨酸转氨甲酰酶缺乏症女性患者早期原位肝移植的发育结局
Pediatrics. 2004 Oct;114(4):e523-6. doi: 10.1542/peds.2004-0198.

引用本文的文献

1
Novel Treatment Strategy for Patients With Urea Cycle Disorders: Pharmacological Chaperones Enhance Enzyme Stability and Activity in Patient-Derived Liver Disease Models.尿素循环障碍患者的新型治疗策略:药理伴侣增强患者来源肝病模型中的酶稳定性和活性
J Inherit Metab Dis. 2025 May;48(3):e70043. doi: 10.1002/jimd.70043.
2
Understanding the Natural History and the Effects of Current Therapeutic Strategies on Urea Cycle Disorders: Insights from the UCD Spanish Registry.了解尿素循环障碍的自然史及当前治疗策略的效果:来自西班牙尿素循环障碍注册研究的见解
Nutrients. 2025 Mar 28;17(7):1173. doi: 10.3390/nu17071173.
3
Identification of novel variants in carbamoyl phosphate synthetase 1 gene and comparative pathogenicity assessments of CPS1 missense variants following ACMG/AMP-ClinGen recommendation for computational tools.
根据美国医学遗传学与基因组学学会(ACMG)/临床基因组资源(ClinGen)针对计算工具的建议,鉴定氨甲酰磷酸合成酶1基因中的新型变异,并对CPS1错义变异进行致病性比较评估。
Mol Genet Metab Rep. 2025 Mar 22;43:101208. doi: 10.1016/j.ymgmr.2025.101208. eCollection 2025 Jun.
4
Establishment and evaluation of a method for measuring ornithine transcarbamylase activity in micro blood of neonates.新生儿微量血鸟氨酸转氨甲酰酶活性测定方法的建立与评价
Orphanet J Rare Dis. 2025 Jan 8;20(1):9. doi: 10.1186/s13023-025-03529-2.
5
Carbamoly-phosphate synthetase 1 (CPS1) deficiency: A tertiary center retrospective cohort study and literature review.氨基甲酰磷酸合成酶1(CPS1)缺乏症:一项三级中心回顾性队列研究及文献综述。
Mol Genet Metab Rep. 2024 Oct 18;41:101156. doi: 10.1016/j.ymgmr.2024.101156. eCollection 2024 Dec.
6
Revisiting the Roles of Catalytic Residues in Human Ornithine Transcarbamylase.重新审视人类鸟氨酸转氨甲酰酶中催化残基的作用。
Biochemistry. 2024 Jul 16;63(14):1858-1875. doi: 10.1021/acs.biochem.4c00206. Epub 2024 Jun 28.
7
Are asymptomatic carriers of OTC deficiency always asymptomatic? A multicentric retrospective study of risk using the UCDC longitudinal study database.OTC 缺乏症的无症状携带者是否一直无症状?使用 UCDC 纵向研究数据库的多中心回顾性风险研究。
Mol Genet Genomic Med. 2024 Apr;12(4):e2443. doi: 10.1002/mgg3.2443.
8
Genetic and functional correction of argininosuccinate lyase deficiency using CRISPR adenine base editors.使用 CRISPR 腺嘌呤碱基编辑器对精氨琥珀酸裂解酶缺乏症进行遗传和功能矫正。
Am J Hum Genet. 2024 Apr 4;111(4):714-728. doi: 10.1016/j.ajhg.2024.03.004.
9
Liver transplantation in ornithine transcarbamylase deficiency: A retrospective multicentre cohort study.鸟氨酸转氨甲酰酶缺乏症的肝移植:一项回顾性多中心队列研究。
Mol Genet Metab Rep. 2023 Nov 5;37:101020. doi: 10.1016/j.ymgmr.2023.101020. eCollection 2023 Dec.
10
Datamining approaches for examining the low prevalence of N-acetylglutamate synthase deficiency and understanding transcriptional regulation of urea cycle genes.数据挖掘方法研究 N-乙酰谷氨酸合酶缺乏症的低患病率,并了解尿素循环基因的转录调控。
J Inherit Metab Dis. 2024 Nov;47(6):1175-1193. doi: 10.1002/jimd.12687. Epub 2023 Nov 5.